Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...

Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

Innoviva, Inc. ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Q4 2024 Earnings Call Transcript February 4, 2025 Dassault Systèmes SE beats earnings expectations. Reported EPS is $0.43, ...

Carrier Global Corporation ( NYSE: CARR) Q4 2024 Earnings Conference Call February 11, 2025 7:30 AM ET Michael Rednor - VP, IR David Gitlin - Chairman & CEO Patrick Goris - SVP & CFO ...

Takeda’s oral orexin receptor 2 agonist oveporexton could eventually hit peak sales between $2 billion and $3 billion, Takeda noted in its presentation ... a lot from BMS’ experience ...